SCIENCE-BOOK 29.04.2025 - Flipbook - Page 5
FILLERS
Safety pro昀椀le
Summary of the publication:
01
Pegylated Hyaluronic Acid Dermal Filler Injections
in a Patient with Titanium Facial Implants: A Case Report
BEFORE
AFTER
Authors: Panithaporn D. I Published: 16.12.2024
INTRODUCTION
Fig. 1: Photographs taken before treatment and during follow-up.
Titanium facial implants are widely used in reconstructive surgery due to their
strength, durability, and biocompatibility; however, they may occasionally cause
aesthetic issues such as contour irregularities or visible edges beneath thin skin.
The use of hyaluronic acid (HA) fillers in such patients has been limited by concerns
about tissue reactions and compatibility with implanted materials.
KEY MESSAGES
This report describes the first documented use of pegylated hyaluronic acid (PEG-HA)
dermal fillers in a patient with multiple facial titanium implants. The case involved a
28-year-old male with mandibular, maxillary, zygomatic, and chin titanium plates placed
7 years earlier. The patient sought facial contour enhancement and tightening. Neauvia
Intense (PEGDE-crosslinked HA 26 mg/mL with glycine and L-proline) was injected in the
temporal and zygomatic areas (0.5 cc and 0.3 cc per side, respectively), and Neauvia
Stimulate (PEGDE-HA with CaHA) was applied along the jawline (0.5 cc per side). Follow-up
assessments and touch-up injections were performed at 2.5 weeks and 15 weeks posttreatment. Clinical outcomes were evaluated through photographs and patient feedback.
RESULTS
The patient achieved a more defined and lifted facial contour with improved
lower-face symmetry and projection.
No adverse events, pain, or inflammatory responses were observed during
the entire follow-up period.
Both physician and patient reported high satisfaction with the final aesthetic
outcome. The patient resumed daily activities immediately after treatment.
PEG-HA fillers demonstrated excellent safety and compatibility in a patient
with titanium facial implants.
The PEGDE crosslinking technology provides superior biocompatibility,
reducing immune activation and inflammatory risk.
PEG-HA allows for precise contouring and natural integration with surrounding
tissues, even in surgically altered facial structures.
The case supports the potential use of PEG-HA fillers as an adjunct to
reconstructive surgery or in patients with implanted materials. Larger,
prospective studies are needed to confirm safety and long-term outcomes in
this specific patient population.
CONCLUSION
This case demonstrates that PEGylated hyaluronic acid fillers can be safely
and effectively used for facial contouring in patients with titanium implants. The
favorable biocompatibility and immunomodulatory properties of PEG-crosslinked
HA make it a reliable, minimally invasive alternative for aesthetic enhancement
following reconstructive procedures. The treatment achieved excellent aesthetic
results with no complications, supporting the broader clinical use of PEG-HA fillers
in complex facial anatomies.
Citation: Dissapong Panithaporn. Pegylated Hyaluronic Acid Dermal Filler Injections in a Patient with Titanium Facial Implants: A Case
Report. Clin Case Rep Int. 2024; 8: 1718.
Back to the safety profile page
